18,19-Dehydrobuprenorphine
A semi-synthetic opioid derived from buprenorphine
18,19-Dehydrobuprenorphine is a semi-synthetic opioid derived from buprenorphine. It is a potent analgesic and is primarily used in research settings to study opioid receptor interactions.
Chemical structure and properties[edit]
18,19-Dehydrobuprenorphine is structurally similar to buprenorphine, with the primary difference being the presence of a double bond between the 18 and 19 positions on the molecular structure. This modification can affect the compound's binding affinity and activity at the opioid receptors.
Pharmacology[edit]
18,19-Dehydrobuprenorphine acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. This dual action is similar to that of buprenorphine, but the presence of the additional double bond may alter its pharmacokinetic and pharmacodynamic properties.
Mechanism of action[edit]
The compound binds to the mu-opioid receptors in the central nervous system, leading to analgesic effects. Its action as a kappa-opioid receptor antagonist may contribute to its reduced potential for causing dysphoria compared to full kappa agonists.
Clinical significance[edit]
While 18,19-Dehydrobuprenorphine is not used clinically, its study provides valuable insights into the development of new analgesics with potentially improved safety profiles. Understanding its interaction with opioid receptors can aid in the design of drugs that minimize the risk of opioid addiction and other side effects.
Research applications[edit]
Research involving 18,19-Dehydrobuprenorphine focuses on its receptor binding characteristics and its potential use as a tool in neuroscience to explore opioid receptor function. It is also used in studies aimed at developing new therapeutic agents for pain management.
Related pages[edit]
Gallery[edit]
-
Chemical structure of 18,19-Dehydrobuprenorphine
18,19-Dehydrobuprenorphine[edit]
-
Structure of 18,19-Dehydrobuprenorphine
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
